Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?
Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2024-12 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Clinical infectious diseases |
| container_volume | |
| creator | Piñana, José Luis Carbonell-Asins, Juan A Gómez, Dolores Montoro, Juan Pérez, Ariadna Hernani, Rafael Chorão, Pedro Hernández-Boluda, Juan Carlos Navarro, David Solano, Carlos |
| description | Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to poor outcomes.
We included consecutive CARV infection episodes occurring up to six months after allo-HCT registered in our database from December 2013 to June 2023 at two Spanish transplant centers.
Among 426 allo-HCT recipients, 1070 CARV episodes were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressing to LRTD, at a median of 18.6 months post-transplant. The most common CARVs were rhinovirus, respiratory syncytial virus (RSV), and influenza. The LRTD progression rate was 26%, with a 4.9% all-cause mortality rate at 100 days post-CARV detection. Risk factors for LRTD progression included graft-versus-host disease prophylaxis [odds ratio (OR) 3.08], corticosteroid use (0.1 to |
| doi_str_mv | 10.1093/cid/ciae602 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146846781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146846781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c177t-59bffa68a74041c8e7d2f7e9f7378ce4f525793d179de5036137e92e9435cd333</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMobk6vvJdcClJNmqZJvZEx_IKBoNXbkqUnM9I2W5JO9u-tbHpxOAfeh5fDg9A5JdeUFOxG23oYBTlJD9CYciaSnBf0cLgJl0kmmRyhkxC-CKFUEn6MRqzIuSBUjNH3zLVt39m4TaZ63VsPNX6FsLJeRee3-MP6PuDnzoCO1nXhFk9x-elBRRwdnrtumZTgWxx6v7Eb5wNWJoLH06ZxS-jAavwWocUzaBpcetWFVaO6eHeKjoxqApzt9wS9P9yXs6dk_vL4PJvOE02FiAkvFsaoXCqRkYxqCaJOjYDCCCakhszwlIuC1VQUNXDCcsqGNIUiY1zXjLEJutz1rrxb9xBi1dqgh2dUB64PFaNZLrNcSDqgVztUexeCB1OtvG2V31aUVL-mq8F0tTc90Bf74n7RQv3P_qllPx-9e8M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146846781</pqid></control><display><type>article</type><title>Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Piñana, José Luis ; Carbonell-Asins, Juan A ; Gómez, Dolores ; Montoro, Juan ; Pérez, Ariadna ; Hernani, Rafael ; Chorão, Pedro ; Hernández-Boluda, Juan Carlos ; Navarro, David ; Solano, Carlos</creator><creatorcontrib>Piñana, José Luis ; Carbonell-Asins, Juan A ; Gómez, Dolores ; Montoro, Juan ; Pérez, Ariadna ; Hernani, Rafael ; Chorão, Pedro ; Hernández-Boluda, Juan Carlos ; Navarro, David ; Solano, Carlos</creatorcontrib><description>Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to poor outcomes.
We included consecutive CARV infection episodes occurring up to six months after allo-HCT registered in our database from December 2013 to June 2023 at two Spanish transplant centers.
Among 426 allo-HCT recipients, 1070 CARV episodes were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressing to LRTD, at a median of 18.6 months post-transplant. The most common CARVs were rhinovirus, respiratory syncytial virus (RSV), and influenza. The LRTD progression rate was 26%, with a 4.9% all-cause mortality rate at 100 days post-CARV detection. Risk factors for LRTD progression included graft-versus-host disease prophylaxis [odds ratio (OR) 3.08], corticosteroid use (0.1 to <30 mg/day: OR 2.44; ≥30 mg/day: OR 5.19), absolute lymphocyte count (ALC) <1 × 10^9/L (OR 1.60), fever at CARV screening (OR 4.27), RSV (OR 2.46), and human metapneumovirus (HMPV) [OR 2.76]. Risk factors for 100-day all-cause mortality included HLA mismatch [hazard ratio (HR) 2.49]; corticosteroid use (0.1 to <30 mg/day: HR 3.87; ≥30 mg/day: HR 5.77); ALC <1 × 10^9/L (HR 2.44); neutropenia <0.5 × 10^9/L (HR 6.74), and age ≥ 40 years (HR 4.85).
Recipients with profound and prolonged immunosuppression remain at risk for severe CARV infection outcomes late after allo-HCT, necessitating intensive clinical monitoring for respiratory symptoms.</description><identifier>ISSN: 1058-4838</identifier><identifier>ISSN: 1537-6591</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciae602</identifier><identifier>PMID: 39657017</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical infectious diseases, 2024-12</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c177t-59bffa68a74041c8e7d2f7e9f7378ce4f525793d179de5036137e92e9435cd333</cites><orcidid>0000-0002-6960-078X ; 0000-0001-6741-971X ; 0000-0001-8533-2562</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39657017$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piñana, José Luis</creatorcontrib><creatorcontrib>Carbonell-Asins, Juan A</creatorcontrib><creatorcontrib>Gómez, Dolores</creatorcontrib><creatorcontrib>Montoro, Juan</creatorcontrib><creatorcontrib>Pérez, Ariadna</creatorcontrib><creatorcontrib>Hernani, Rafael</creatorcontrib><creatorcontrib>Chorão, Pedro</creatorcontrib><creatorcontrib>Hernández-Boluda, Juan Carlos</creatorcontrib><creatorcontrib>Navarro, David</creatorcontrib><creatorcontrib>Solano, Carlos</creatorcontrib><title>Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to poor outcomes.
We included consecutive CARV infection episodes occurring up to six months after allo-HCT registered in our database from December 2013 to June 2023 at two Spanish transplant centers.
Among 426 allo-HCT recipients, 1070 CARV episodes were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressing to LRTD, at a median of 18.6 months post-transplant. The most common CARVs were rhinovirus, respiratory syncytial virus (RSV), and influenza. The LRTD progression rate was 26%, with a 4.9% all-cause mortality rate at 100 days post-CARV detection. Risk factors for LRTD progression included graft-versus-host disease prophylaxis [odds ratio (OR) 3.08], corticosteroid use (0.1 to <30 mg/day: OR 2.44; ≥30 mg/day: OR 5.19), absolute lymphocyte count (ALC) <1 × 10^9/L (OR 1.60), fever at CARV screening (OR 4.27), RSV (OR 2.46), and human metapneumovirus (HMPV) [OR 2.76]. Risk factors for 100-day all-cause mortality included HLA mismatch [hazard ratio (HR) 2.49]; corticosteroid use (0.1 to <30 mg/day: HR 3.87; ≥30 mg/day: HR 5.77); ALC <1 × 10^9/L (HR 2.44); neutropenia <0.5 × 10^9/L (HR 6.74), and age ≥ 40 years (HR 4.85).
Recipients with profound and prolonged immunosuppression remain at risk for severe CARV infection outcomes late after allo-HCT, necessitating intensive clinical monitoring for respiratory symptoms.</description><issn>1058-4838</issn><issn>1537-6591</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kF1LwzAUhoMobk6vvJdcClJNmqZJvZEx_IKBoNXbkqUnM9I2W5JO9u-tbHpxOAfeh5fDg9A5JdeUFOxG23oYBTlJD9CYciaSnBf0cLgJl0kmmRyhkxC-CKFUEn6MRqzIuSBUjNH3zLVt39m4TaZ63VsPNX6FsLJeRee3-MP6PuDnzoCO1nXhFk9x-elBRRwdnrtumZTgWxx6v7Eb5wNWJoLH06ZxS-jAavwWocUzaBpcetWFVaO6eHeKjoxqApzt9wS9P9yXs6dk_vL4PJvOE02FiAkvFsaoXCqRkYxqCaJOjYDCCCakhszwlIuC1VQUNXDCcsqGNIUiY1zXjLEJutz1rrxb9xBi1dqgh2dUB64PFaNZLrNcSDqgVztUexeCB1OtvG2V31aUVL-mq8F0tTc90Bf74n7RQv3P_qllPx-9e8M</recordid><startdate>20241205</startdate><enddate>20241205</enddate><creator>Piñana, José Luis</creator><creator>Carbonell-Asins, Juan A</creator><creator>Gómez, Dolores</creator><creator>Montoro, Juan</creator><creator>Pérez, Ariadna</creator><creator>Hernani, Rafael</creator><creator>Chorão, Pedro</creator><creator>Hernández-Boluda, Juan Carlos</creator><creator>Navarro, David</creator><creator>Solano, Carlos</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6960-078X</orcidid><orcidid>https://orcid.org/0000-0001-6741-971X</orcidid><orcidid>https://orcid.org/0000-0001-8533-2562</orcidid></search><sort><creationdate>20241205</creationdate><title>Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?</title><author>Piñana, José Luis ; Carbonell-Asins, Juan A ; Gómez, Dolores ; Montoro, Juan ; Pérez, Ariadna ; Hernani, Rafael ; Chorão, Pedro ; Hernández-Boluda, Juan Carlos ; Navarro, David ; Solano, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c177t-59bffa68a74041c8e7d2f7e9f7378ce4f525793d179de5036137e92e9435cd333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piñana, José Luis</creatorcontrib><creatorcontrib>Carbonell-Asins, Juan A</creatorcontrib><creatorcontrib>Gómez, Dolores</creatorcontrib><creatorcontrib>Montoro, Juan</creatorcontrib><creatorcontrib>Pérez, Ariadna</creatorcontrib><creatorcontrib>Hernani, Rafael</creatorcontrib><creatorcontrib>Chorão, Pedro</creatorcontrib><creatorcontrib>Hernández-Boluda, Juan Carlos</creatorcontrib><creatorcontrib>Navarro, David</creatorcontrib><creatorcontrib>Solano, Carlos</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piñana, José Luis</au><au>Carbonell-Asins, Juan A</au><au>Gómez, Dolores</au><au>Montoro, Juan</au><au>Pérez, Ariadna</au><au>Hernani, Rafael</au><au>Chorão, Pedro</au><au>Hernández-Boluda, Juan Carlos</au><au>Navarro, David</au><au>Solano, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2024-12-05</date><risdate>2024</risdate><issn>1058-4838</issn><issn>1537-6591</issn><eissn>1537-6591</eissn><abstract>Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to poor outcomes.
We included consecutive CARV infection episodes occurring up to six months after allo-HCT registered in our database from December 2013 to June 2023 at two Spanish transplant centers.
Among 426 allo-HCT recipients, 1070 CARV episodes were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressing to LRTD, at a median of 18.6 months post-transplant. The most common CARVs were rhinovirus, respiratory syncytial virus (RSV), and influenza. The LRTD progression rate was 26%, with a 4.9% all-cause mortality rate at 100 days post-CARV detection. Risk factors for LRTD progression included graft-versus-host disease prophylaxis [odds ratio (OR) 3.08], corticosteroid use (0.1 to <30 mg/day: OR 2.44; ≥30 mg/day: OR 5.19), absolute lymphocyte count (ALC) <1 × 10^9/L (OR 1.60), fever at CARV screening (OR 4.27), RSV (OR 2.46), and human metapneumovirus (HMPV) [OR 2.76]. Risk factors for 100-day all-cause mortality included HLA mismatch [hazard ratio (HR) 2.49]; corticosteroid use (0.1 to <30 mg/day: HR 3.87; ≥30 mg/day: HR 5.77); ALC <1 × 10^9/L (HR 2.44); neutropenia <0.5 × 10^9/L (HR 6.74), and age ≥ 40 years (HR 4.85).
Recipients with profound and prolonged immunosuppression remain at risk for severe CARV infection outcomes late after allo-HCT, necessitating intensive clinical monitoring for respiratory symptoms.</abstract><cop>United States</cop><pmid>39657017</pmid><doi>10.1093/cid/ciae602</doi><orcidid>https://orcid.org/0000-0002-6960-078X</orcidid><orcidid>https://orcid.org/0000-0001-6741-971X</orcidid><orcidid>https://orcid.org/0000-0001-8533-2562</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2024-12 |
| issn | 1058-4838 1537-6591 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3146846781 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T11%3A46%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Community-Acquired%20Respiratory%20Virus%20Infections:%20A%20Threat%20to%20Long-Term%20survivors%20after%20Allogeneic%20Stem%20Cell%20Transplant?&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Pi%C3%B1ana,%20Jos%C3%A9%20Luis&rft.date=2024-12-05&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciae602&rft_dat=%3Cproquest_cross%3E3146846781%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146846781&rft_id=info:pmid/39657017&rfr_iscdi=true |